PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

주식 순위 #1439
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
주가
$36.89
시가총액
$15.25B
변동 (1일)
-1.28%
변동 (1년)
144.12%
국가
TW
거래 PharmaEssentia Corporation (6446)

카테고리

Healthcare
PharmaEssentia Corporation (6446)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 23.96
PharmaEssentia Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 23.96입니다. 2023년 말 기준 P/S 비율은 22.06였습니다.
PharmaEssentia Corporation의 P/S 비율 기록 (2010 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
2026 (TTM) 23.96 16.52%
2024 20.56 -6.80%
2023 22.06 -53.07%
2022 47.01 -58.98%
2021 114.59 181.19%
2020 40.75 -46.81%
2019 76.61 -94.54%
2018 1.40K -81.75%
2017 7.68K 27.57%
2016 6.02K 95.48%
2015 3.08K 61.64%
2014 1.91K 276.50%
2013 506.34 -45.75%
2012 933.30 -41.98%
2011 1.61K 237.00%
2010 477.29 0.00%
유사 기업 또는 경쟁사의 P/S 비율